Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares
Medexus (OTCQX: MEDXF / TSX: MDP) announced a normal course issuer bid (NCIB) accepted by the Toronto Stock Exchange, allowing purchases of up to 2,983,650 common shares, approximately 10% of the public float. As of November 12, 2025 there were 32,420,060 shares outstanding and a public float of 29,836,506. Purchases may begin on November 24, 2025 and run through November 23, 2026, will be funded from the company's general funds, executed on the TSX or alternative Canadian trading systems, and any shares purchased will be cancelled. The six‑month ADTV to October 31, 2025 was 40,066, limiting daily purchases to 10,016 shares under TSX rules, excluding block purchase exceptions.
Medexus (OTCQX: MEDXF / TSX: MDP) ha annunciato un'offerta normale di riacquisto azionario (NCIB) accettata dalla Toronto Stock Exchange, che permette l'acquisto di fino a 2.983.650 azioni ordinarie, circa 10% del flottante pubblico. Al 12 novembre 2025 ci sono 32.420.060 azioni in circolazione e un flottante pubblico di 29.836.506. Gli acquisti possono iniziare il 24 novembre 2025 e proseguire fino al 23 novembre 2026, saranno finanziati dai fondi generali dell'azienda, eseguiti sulla TSX o su sistemi di trading canadesi alternativi, e le azioni acquistate saranno annullate. Il ADTV semestrale al 31 ottobre 2025 era di 40.066, limitando gli acquisti giornalieri a 10.016 azioni secondo le norme TSX, escludendo le eccezioni di blocco.
Medexus (OTCQX: MEDXF / TSX: MDP) anunció una oferta de recompra de acciones normal (NCIB) aceptada por la Bolsa de Toronto, que permite compras de hasta 2.983.650 acciones comunes, aproximadamente el 10% del float público. A partir del 12 de noviembre de 2025 había 32.420.060 acciones en circulación y un float público de 29.836.506. Las compras pueden comenzar el 24 de noviembre de 2025 y continuar hasta el 23 de noviembre de 2026, se financiarán con los fondos generales de la empresa, se ejecutarán en la TSX o en sistemas de negociación canadienses alternativos, y cualquier acción adquirida será cancelada. El ADTV semestral hasta el 31 de octubre de 2025 fue de 40.066, limitando las compras diarias a 10.016 acciones conforme a las reglas de la TSX, sin contar las excepciones de compra en bloque.
메덱스(MEDXF/TSX: MDP)가 토론토 증권거래소에서 승인된 정상 주식환매 공고(NCIB)를 발표했습니다. 이는 최대 2,983,650주 일반주까지 매입을 허용하며, 이는 대략 공개 유통주식의 10%에 해당합니다. 2025년 11월 12일 기준 발행주식은 32,420,060주이고 공개유통 주식은 29,836,506주입니다. 매입은 2025년 11월 24일에 시작해 2026년 11월 23일까지 진행될 수 있으며, 회사의 일반 기금으로 자금을 조달하고 TSX나 대체 캐나다 거래 시스템에서 실행되며, 매입된 모든 주식은 소각됩니다. 2025년 10월 31일 기준 6개월 ADTV는 40,066주였고, TSX 규정에 따라 일일 매입 상한은 10,016주로 제한되며 대량 매입 예외는 제외됩니다.
Medexus (OTCQX: MEDXF / TSX: MDP) a annoncé une offre d'achat d'actions dans le cadre d'un cours normal (NCIB) acceptée par la Bourse de Toronto, permettant des achats allant jusqu'à 2 983 650 actions ordinaires, soit environ 10 % du flottant public. Au 12 novembre 2025, il y avait 32 420 060 actions en circulation et un flottant public de 29 836 506. Les achats peuvent commencer le 24 novembre 2025 et se dérouler jusqu'au 23 novembre 2026, seront financés par les fonds propres généraux de l'entreprise, exécutés sur le TSX ou sur des systèmes de négociation canadiens alternatifs, et les actions achetées seront annulées. Le ADTV sur six mois jusqu'au 31 octobre 2025 était de 40 066, limitant les achats quotidiens à 10 016 actions selon les règles du TSX, à l'exclusion des exceptions d'achats en bloc.
Medexus (OTCQX: MEDXF / TSX: MDP) hat eine normale Aktienrückkaufmaßnahme (NCIB) angekündigt, die von der Toronto Stock Exchange genehmigt wurde und Käufe von bis zu 2.983.650 Stammaktien ermöglicht, etwa 10% des öffentlichen Streubesitzes. Zum 12. November 2025 gab es 32.420.060 ausstehende Aktien und einen öffentlichen Streubesitz von 29.836.506. Käufe können am 24. November 2025 beginnen und bis zum 23. November 2026 dauern, werden aus den allgemeinen Mitteln des Unternehmens finanziert, an der TSX oder an alternativen kanadischen Handelsplätzen ausgeführt, und gekaufte Aktien werden gelöscht. Der sechsmonatige ADTV bis zum 31. Oktober 2025 betrug 40.066 und begrenzt tägliche Käufe auf 10.016 Aktien gemäß TSX-Regeln, Ausnahmen für Blockkäufe ausgenommen.
Medexus (OTCQX: MEDXF / TSX: MDP) أعلن عن عرض عادي لإعادة شراء الأسهم (NCIB) مقبول من بورصة تورنتو، يسمح بعمليات شراء تصل إلى 2,983,650 سهماً عادياً، بما يقرب من 10% من الأسهم المتداولة علناً. حتى 12 نوفمبر 2025 كان هناك 32,420,060 سهماً قائماً وعرض عام من 29,836,506. يمكن أن تبدأ الشراءات في 24 نوفمبر 2025 وتستمر حتى 23 نوفمبر 2026، وسيتم تمويلها من أموال الشركة العامة، وتنفيذها على TSX أو أنظمة تداول كندية بديلة، وأي أسهم مُشتراة ستُلغى. كان ADTV خلال ستة أشهر حتى 31 أكتوبر 2025 هو 40,066، مما يحد من عمليات الشراء اليومية إلى 10,016 سهماً وفقاً لقواعد TSX، باستثناء استثناءات الشراء بالجملة.
- NCIB authorizes purchase of 2,983,650 shares (~10% public float)
- Purchased shares will be cancelled, reducing outstanding share count
- NCIB window runs Nov 24, 2025–Nov 23, 2026, providing execution flexibility
- NCIB purchases will be funded from general funds, reducing cash resources
- Daily buy limit of 10,016 shares may slow completion under ADTV rules
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 20, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the Toronto Stock Exchange has accepted Medexus's notice of intention to make a normal course issuer bid, or NCIB, for its common shares (TSX: MDP). Under the NCIB, Medexus may purchase for cancellation up to 2,983,650 common shares, representing approximately
"We intend to carefully monitor the market price of the common shares," said Brendon Buschman, Medexus's Chief Financial Officer. "Purchases under this new NCIB could be an appropriate use of our available funds, where we believe the market price of the common shares may be undervalued. Any such purchases we make will benefit the company and its investors by seeking to uphold a liquid, stable, and orderly market for our common shares."
Purchases under the NCIB may commence on November 24, 2025 and continue through November 23, 2026 or such earlier date as Medexus completes the maximum aggregate purchases permitted under the NCIB. The NCIB will be conducted by means of open market transactions through the facilities of the TSX or alternative Canadian trading systems at the prevailing market price on the TSX or applicable alternative Canadian trading system at the time of purchase or as otherwise permitted. The NCIB will be funded using Medexus's general funds. Any common shares purchased by Medexus under the NCIB will be cancelled.
During the six months ended October 31, 2025, the average daily trading volume, or ADTV, of the common shares on the TSX was 40,066. Accordingly, under TSX rules and policies, purchases under the NCIB on any trading day will be limited to a maximum of 10,016 common shares, being
About Medexus
Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of hematology and hematology-oncology and rheumatology and allergy. For more information about Medexus and its product portfolio, please see the company's corporate website at www.medexus.com and its filings on SEDAR+ at www.sedarplus.ca.
Contacts
Ken d'Entremont | CEO, Medexus Pharmaceuticals
Tel: 905-676-0003 | Email: ken.dentremont@medexus.com
Brendon Buschman | CFO, Medexus Pharmaceuticals
Tel: 416-577-6216 | Email: brendon.buschman@medexus.com
Victoria Rutherford | Adelaide Capital
Tel: 480-625-5772 | Email: victoria@adcap.ca
Forward-looking statements
Certain statements in this news release contain forward-looking information within the meaning of applicable securities laws, also known and/or referred to as "forward-looking information" or "forward-looking statements". The words "anticipates", "believes", "budget", "potential", "targets", "could", "estimates", "expects", "forecasts", "goals", "intends", "may", "might", "objective", "outlook", "plans", "projects", "schedule", "should", "will", "would", "prospects", and "vision", or similar words, phrases, or expressions, are often intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words, phrases, or expressions. Specific forward-looking statements in this news release include, but are not limited to, information contained in statements regarding potential future purchases of Medexus's common shares under the NCIB and Medexus's overall capital allocation strategy. The forward-looking statements and information included in this news release are based on Medexus's current expectations and assumptions, including factors or assumptions that were applied in drawing a conclusion or making a forecast or projection, and including assumptions based on regulatory guidelines, historical trends, current conditions, and expected future developments, and including, but not limited to, Medexus's expectations with respect to cash flow generation and the availability of funds. Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. Medexus cautions that, although the assumptions are believed to be reasonable in the circumstances, these risks and uncertainties mean that actual results could differ, and could differ materially, from the expectations contemplated by the forward-looking statements. Material risk factors include, but are not limited to, those set out in Medexus's materials filed with the Canadian securities regulatory authorities from time to time, including Medexus's most recent annual information form and management's discussion and analysis. Accordingly, undue reliance should not be placed on these forward-looking statements, which are made only as of the date of this news release. Other than as specifically required by law, Medexus undertakes no obligation to update any forward-looking statements to reflect new information, subsequent or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/275259
FAQ
What size NCIB did Medexus (MEDXF) announce on November 20, 2025?
When can Medexus (MEDXF) start buying shares under the NCIB?
How will Medexus (MEDXF) fund its share repurchases under the NCIB?
How many shares can Medexus (MEDXF) buy per trading day under TSX rules?
What happens to shares purchased by Medexus (MEDXF) under the NCIB?
